Shijiazhuang Yiling Pharmaceutical Co., Ltd.

SZSE:002603 Stock Report

Market Cap: CN¥27.2b

Shijiazhuang Yiling Pharmaceutical Balance Sheet Health

Financial Health criteria checks 5/6

Shijiazhuang Yiling Pharmaceutical has a total shareholder equity of CN¥11.5B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 11.1%. Its total assets and total liabilities are CN¥16.6B and CN¥5.1B respectively. Shijiazhuang Yiling Pharmaceutical's EBIT is CN¥150.9M making its interest coverage ratio 14.4. It has cash and short-term investments of CN¥916.3M.

Key information

11.1%

Debt to equity ratio

CN¥1.27b

Debt

Interest coverage ratio14.4x
CashCN¥916.31m
EquityCN¥11.49b
Total liabilitiesCN¥5.13b
Total assetsCN¥16.61b

Recent financial health updates

Recent updates

Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Business Is Trailing The Industry But Its Shares Aren't

Nov 26
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Business Is Trailing The Industry But Its Shares Aren't

Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 04
Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Using Too Much Debt?

Sep 25
Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Using Too Much Debt?

Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Subdued P/S Might Signal An Opportunity

Aug 07
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Subdued P/S Might Signal An Opportunity

Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Has Announced That Its Dividend Will Be Reduced To CN¥0.30

Jul 15
Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Has Announced That Its Dividend Will Be Reduced To CN¥0.30

Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) A Risky Investment?

May 26
Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) A Risky Investment?

Weak Statutory Earnings May Not Tell The Whole Story For Shijiazhuang Yiling Pharmaceutical (SZSE:002603)

May 05
Weak Statutory Earnings May Not Tell The Whole Story For Shijiazhuang Yiling Pharmaceutical (SZSE:002603)

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Analysts Just Cut Their EPS Forecasts Substantially

May 02
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Analysts Just Cut Their EPS Forecasts Substantially

Should You Be Adding Shijiazhuang Yiling Pharmaceutical (SZSE:002603) To Your Watchlist Today?

Mar 01
Should You Be Adding Shijiazhuang Yiling Pharmaceutical (SZSE:002603) To Your Watchlist Today?

Financial Position Analysis

Short Term Liabilities: 002603's short term assets (CN¥6.2B) exceed its short term liabilities (CN¥3.9B).

Long Term Liabilities: 002603's short term assets (CN¥6.2B) exceed its long term liabilities (CN¥1.2B).


Debt to Equity History and Analysis

Debt Level: 002603's net debt to equity ratio (3.1%) is considered satisfactory.

Reducing Debt: 002603's debt to equity ratio has increased from 0% to 11.1% over the past 5 years.

Debt Coverage: 002603's debt is well covered by operating cash flow (26.2%).

Interest Coverage: 002603's interest payments on its debt are well covered by EBIT (14.4x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 18:26
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shijiazhuang Yiling Pharmaceutical Co., Ltd. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhengwu WuAJ Securities Co., Ltd
Shuchang LiuChangjiang Securities Co. LTD.
Weiying TuChina International Capital Corporation Limited